All Issue

2021 Vol.51, Issue 4 Preview Page

Original Article

31 December 2021. pp. 178-188
Abstract
References
1

Davison AJ, Scott JE. The complete DNA sequence of varicella-zoster virus. J Gen Virol 1986;67:1759-816.

10.1099/0022-1317-67-9-17593018124
2

Gershon AA, Gershon MD. Pathogenesis and current approaches to control of varicella-zoster virus infections. Clin Microbiol Rev 2013;26:728-43.

10.1128/CMR.00052-1324092852PMC3811230
3

Zerboni L, Sen N, Oliver SL, Arvin AM. Molecular mechanisms of varicella zoster virus pathogenesis. Nat Rev Microbiol 2014;12:197-210.

10.1038/nrmicro321524509782PMC4066823
4

Arvin AM, Moffat JF, Sommer M, Oliver S, Che X, Vleck S, et al. Varicella-zoster virus T cell tropism and the pathogenesis of skin infection. Curr Top Microbiol Immunol 2010;342:182-209.

10.1007/82_2010_2920397071PMC4077053
5

Gilden DH, Kleinschmidt-DeMasters BK, Laguardia JJ, Mahalingam R, Cohrs RJ. Neurologic complications of the reactivation of varicella-zoster virus. N Engl J Med 2000;342:635-45.

10.1056/NEJM20000302342090610699164
6

Kennedy PGE, Gershon AA. Clinical features of varicella-zoster virus infection. Viruses 2018;10:609.

10.3390/v1011060930400213PMC6266119
7

Hall S, Maupin T, Seward J, Jumaan AO, Peterson C, Goldman G, et al. Second varicella infections: are they more common than previously thought? Pediatrics 2002;109:1068-73.

10.1542/peds.109.6.106812042544
8

Takahashi M, Otsuka T, Okuno Y, Asano Y, Yazaki T. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 1974;2:1288-90.

10.1016/S0140-6736(74)90144-5
9

D'Hondt E, Berge E, Colinet G, Duchene M, Peetermans J. Production and quality control of the Oka-strain live varicella vaccine. Postgrad Med J 1985;61:53-6.

10

Freer G, Pistello M. Varicella-zoster virus infection: natural history, clinical manifestations, immunity and current and future vaccination strategies. New Microbiol 2018;41:95-105.

11

Gershon AA. The current status of live attenuated varicella vaccine. Arch Virol Suppl 2001;1-6.

10.1007/978-3-7091-6259-0_111339539
12

Sohn YM, Park CY, Hwang KK, Woo GJ, Park SY. Safety and immunogenicity of live attenuated varicella virus vaccine (MAV/06 strain). J Korean Ped 1994;37:1405-13.

13

Jeon JS, Won YH, Kim IK, Ahn JH, Shin OS, Kim JH, et al. Analysis of single nucleotide polymorphism among varicella-zoster virus and identification of vaccine-specific sites. Virology 2016;496:277-86.

10.1016/j.virol.2016.06.01727376245
14

Cricca M, Morselli-Labate AM, Venturoli S, Ambretti S, Gentilomi GA, Gallinella G, et al. Viral DNA load, physical status and E2/E6 ratio as markers to grade HPV16 positive women for high-grade cervical lesions. Gynecol Oncol 2007;106:549-57.

10.1016/j.ygyno.2007.05.00417568661
15

Schmutzhard J, Merete Riedel H, Zweygberg Wirgart B, Grillner L. Detection of herpes simplex virus type 1, herpes simplex virus type 2 and varicella-zoster virus in skin lesions. Comparison of real-time PCR, nested PCR and virus isolation. J Clin Virol 2004;29:120-6.

10.1016/S1386-6532(03)00113-6
16

Hedrick PW. Genetics of population. Jones and Bartlett publishers 2010;103-5.

17

Gregori J, Perales C, Rodriguez-Frias F, Esteban JI, Quer J, Domingo E. Viral quasispecies complexity measures. Virology 2016;493:227-37.

10.1016/j.virol.2016.03.01727060566
18

Baudoux L, Defechereux P, Schoonbroodt S, Merville MP, Rentier B, Piette J. Mutational analysis of varicella-zoster virus major immediate-early protein IE62. Nucleic Acids Res 1985;23:1341-9.

10.1093/nar/23.8.13417753624PMC306859
19

Barrett-Muir W, Hawrami K, Clarke J, Breuer J. Investigation of varicella-zoster virus variation by heteroduplex mobility assay. Arch Virol Suppl 2001;17-25.

10.1007/978-3-7091-6259-0_311339546
20

Sen N, Sommer M, Che X, White K, Ruyechan WT, Arvin AM. Varicella-zoster virus immediate-early protein 62 blocks interferon regulatory factor 3 (IRF3) phosphorylation at key serine residues: a novel mechanism of IRF3 inhibition among herpesviruses. J Virol 2010;84:9240-53.

10.1128/JVI.01147-1020631144PMC2937611
21

Gomi Y, Sunamachi H, Mori Y, Nagaike K, Takahashi M, Yamanishi K. Comparison of the complete DNA sequences of the Oka varicella vaccine and its parental virus. J Virol 2002;76:11447-59.

10.1128/JVI.76.22.11447-11459.200212388706PMC136748
22

Tillieux SL, Halsey WS, Thomas ES, Voycik JJ, Sathe GM, Vassilev V. Complete DNA sequences of two oka strain varicella-zoster virus genomes. J Virol 2008;82:11023-44.

10.1128/JVI.00777-0818787000PMC2573284
23

Quinlivan M, Breuer J. Clinical and molecular aspects of the live attenuated Oka varicella vaccine. Rev Med Virol 2014;24:254-73.

10.1002/rmv.178924687808
24

Kim SC, Won YH, Park JS, Jeon JS, Ahn JH, Song MJ, et al. Vaccine-type mutations identified in Varicella zoster virus passaged in cell culture. Virus Res 2018;245:62-8.

10.1016/j.virusres.2017.12.00429242077
25

Kim MH, Jeon JS, Kim IK, Park JS, Park H, Shin OS, et al. Characterization and phylogenetic analysis of Varicella-zoster virus strains isolated from Korean patients. J Microbiol 2017;55:665-72.

10.1007/s12275-017-7171-328752294
26

González-Motos V, Jürgens C, Ritter B, Kropp KA, Durán V, Larsen O, et al. Varicella zoster virus glycoprotein C increases chemokine-mediated leukocyte migration. PLoS Pathog 2017;13:e1006346.

10.1371/journal.ppat.100634628542541PMC5444840
27

Moffat JF, Zerboni L, Kinchington PR, Grose C, Kaneshima H, Arvin AM. Attenuation of the vaccine Oka strain of varicella-zoster virus and role of glycoprotein C in alphaherpesvirus virulence demonstrated in the SCID-hu mouse. J Virol 1998;72:965-74.

10.1128/JVI.72.2.965-974.19989444989PMC124567
28

Plotkin SA, Orenstein WA, Offit PA. Vaccines, 6th ed. Elsevier, 2013.

Information
  • Publisher :The Korean Society for Microbiology
  • Publisher(Ko) :대한미생물학회
  • Journal Title :JOURNAL OF BACTERIOLOGY AND VIROLOGY
  • Volume : 51
  • No :4
  • Pages :178-188
  • Received Date :2021. 08. 30
  • Revised Date :2021. 12. 06
  • Accepted Date : 2021. 12. 06